Trinity Employees Share Expertise at Leading Spring Events and Conferences

Boston, MA, May 15, 2018 – Trinity Partners, a leading global life sciences consulting firm, today announced it will attend several important industry events across the U.S. this month. Covering topics ranging from innovation and endocrinology research to managed care, Trinity leaders are looking forward to presenting on and learning the latest updates in rare disease and patient advocacy, health care expenditure and the patient journey to continue to help clients make informed decisions in today’s continuously evolving business landscape.

Life sciences industry events Trinity Partners will attend include:

  • Intellus Worldwide Summit, May 6-8: Steve Yonish, Kyle Martin and Devon Reimer attended the Intellus Worldwide Summit in Philadelphia. The summit focused on new ways of understanding the patient journey including how insight professionals think about and provide solutions to optimize the patient experience.
  • Innovation Leader’s Deep Dive: Transforming Healthcare, May 16-17: Matt Giambrone will participate in the Innovation Leader’s Deep Dive at the Pulse@MassChallenge healthcare accelerator in Boston to hear best practices to better enable healthcare companies to successfully foster, pilot test and roll out new concepts.
  • American Association of Clinical Endocrinologists (AACE) 27th Annual Scientific and Clinical Congress, May 16-20: Irana Kolev will attend the AACE Scientific and Clinical Congress to hear the latest information on the diagnosis and management of endocrine diseases. Irana will also be presenting a poster for a recent Trinity health economics outreach research (HEOR) study on chronic hypoparathyroidism on May 19 from 10-11 am ET.
  • International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual Meeting, May 19-23: Nandini Hadker, Gavin Miyasato, Zahra Alkhateeb, Amod Athavale and Kalin Hennegan will be attending the ISPOR Annual Meeting in Baltimore to engage in the latest discussions around the role of real-world evidence and digital health in healthcare decision making. Trinity will also be presenting research in 3 poster presentations during ISPOR: a Medicare claims analysis quantifying the degree and impact of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer’s disease sub-specialization among neurologists, along with a Burden of Illness study and systematic literature review assessing the challenges with characterizing and managing hypoactive sexual desire disorder in women.

“At Trinity, we are committed to continuous learning and innovation to ensure we’re at the forefront of topics that matter to our clients,” said Yogesh Soneji, Partner, Trinity Partners. “We look forward to presenting research and continuing to find solutions to the complex business challenges that confront pharmaceutical, biotech, and medical device companies around the globe.”

Trinity Partners to Present on Patient Journey at Eyeforpharma Philadelphia 2018

Boston, MA, April 10, 2018 – Trinity Partners, a leading global life sciences consulting firm, today announced it will participate in eyeforpharma’s 16th Annual Meeting, April 10-11, in Philadelphia, PA.

This year’s eyeforpharma meeting is designed to provide life sciences executives with greater insight into the patient journey. Presenters will highlight strategies to leverage advanced analytics and communication channels and unite organizations around the patient to deliver real value.

“Treatments are becoming more targeted and patients are more involved in the treatment-decision-making process. Whether a product is launched or in clinical development, it’s vital that drug manufacturers understand a patient’s treatment journey from all perspectives – from the patient to the provider to the payer – to make more informed commercial decisions,” Kevin Francis, Principal, Analytics & Insights, Trinity Partners. “We look forward to attending eyeforpharma, connecting with members of the life sciences community and showcasing how to mine the patient journey for insights to guide commercial strategy decision-making.”

At eyeforpharma, Kevin Francis and Jenn Parr, Engagement Manager, will present on understanding and continuously refining the patient treatment journey to help manufacturers along the commercial decision-making process. The session, titled “Commercial Strategy Decision-Making powered by the Patient Journey” will be held on April 10, 2018 from 5:25-5:55 pm.

During the session, Kevin and Jenn will highlight how organizations can develop a patient journey framework that enables a common language across commercial teams, informs data strategy, and provides insights across the product development cycle. Kevin and Jenn will also showcase specific examples for organizations that have leveraged the patient journey for clinical, launch and post-launch decision-making purposes.

Visit Trinity at booth #4 at eyeforpharma to learn more about how you can begin to use the patient journey as the backbone for commercial decision-making.

Trinity employees will also attend several other events and conferences this month focused on gene therapy, rare diseases, specialty pharmacy and more. Events include:

  • The 2018 Yale Healthcare Conference: April 13, New Haven, CT
    • Nandini Hadker will speak on a panel on drug pricing.
  • The Academy of Managed Care Pharmacy (AMCP) 2018 Annual Meeting: April 23, Boston, MA
  • World Orphan Drug Congress USA: April 25, Oxon Hill, MD
  • Asembia’s 2018 Specialty Pharmacy Summit: April 29, Las Vegas, VM
  • The Gene Therapy for Rare Disorders Summit: April 29, Boston, MA

What Rare Disease Day Means to Trinity Partners

Rare Disease Day falls on Wednesday, February 28th. At Trinity, we work closely with many life sciences companies developing treatments for rare disease patients. Research is crucial to the rare community, and we are committed to help raise awareness around the importance of medical representation for individuals with rare diseases and their families. Keep an eye on our social media channels this week for some rare disease-focused updates and read on to learn what Rare Disease Day means to Trinity employees:

“I hope that, one day, rare diseases have as many treatment options and cures as any other disease. Rare diseases deserve to receive attention and be understood like any other condition.” Rachel Halperin, Senior Associate Consultant

“From helping companies develop business cases for rare inherited disorders, to my personal life where I function as a caretaker for a loved one with a rare autonomic/hypermobility disorder, I deal with the challenges presented by rare diseases on a daily basis. I hope that the pharmaceutical ecosystem continues to evolve so that the business cases for these agents become more attractive, spurring innovation in underserved patient populations.”  Consultant

“Rare Disease Day is a reminder of the millions of patients and families affected by rare diseases. It’s also a reminder of how the treatment of rare disease is catalyzing innovations that will revolutionize treatment of rare and non-rare diseases.” Herman Sanchez, Partner

“[Rare Disease Day means] that no one gets left behind. Just because it is a rare disease doesn’t mean we don’t care. I hope more companies will invest in rare diseases and find help for patients who have been overlooked all this time.” Nandini Hadker, Principal

“Rare Disease Day means raising worldwide awareness of rare conditions to help improve the ability to identify and diagnose patients and increase research and development to find effective treatments.  I’ve personally watched my brother struggle for years to find a cause for his symptoms and, now diagnosed with a rare disease, he continues to suffer due to lack of treatments. I hope for him and all others with rare diseases that research continues and the great progress over recent years continues.” Maria Gumina, PhD, Engagement Manager

“Rare Disease Day means an opportunity to recognize the tireless work and strength of communities across the world who fight for recognition and awareness of their conditions that consume their lives. A good friend of mine has Phenylketonuria (PKU), and I’ve seen her overcome obstacles in her everyday life that most people never face. In researching rare diseases as a focus of my work, I’ve learned to be so much more grateful and feel so much more blessed to have two happy, healthy children.” Krista Perry, Principal

Trinity Partners Principal Jillian Godfrey Scaife Discusses Trinity Biosimilar Whitepaper

In a recent article for Managed Healthcare Executive, editor Tracey Walker spoke with Trinity’s Jillian Godfrey Scaife about the findings of Trinity’s recent biosimilar whitepaper. In the article, Jillian highlights key takeaways from the findings. You can read the full story including further insights from Jillian here: http://bit.ly/2Br1FsD

New Report from Trinity Partners Highlights Key Barriers to U.S. Biosimilar Adoption

Complex Pricing Structures, Legal and Regulatory Barriers,
and Clinical Uncertainty Hinder Progress in Biosimilar Market Access

Key findings from the report, which seeks to reveal opportunities to accelerate biosimilar adoption, include the following:

  • Biosimilar pricing to date has not offered the sharp discounts payers expect, after accounting for contract discounts and nuances such as the “rebate trap”;
  • Biologic innovators have taken legal and promotional actions that derail biosimilar commercial success;
  • Providers are not fully comfortable with biosimilars and are interested in seeing more clinical and real-world data; if biosimilars were to attain interchangeability status, this gap in clinical comfort could be minimized

The report, conducted in partnership with Schlesinger Associates, is supported by findings from qualitative market research with medical directors at payer organizations in the United States. The findings are based on historical trends, current market dynamics, and future market access expectations in biosimilars.

“Biosimilar access still lags behind traditional small molecule markets, but there is so much potential for long-term cost savings for payer plans and the U.S. healthcare system as a whole,” said Neal Dunn, Partner, Trinity Partners. “Once interchangeability is achieved, other barriers such as clinical confidence and litigation will fall into place.”

“Each country’s commercial and regulatory landscape is nuanced based on laws, pay structures, and culture, which creates unique environments for market access,” said John Corcoran, Founder and President, Trinity Partners. “Our in-depth knowledge of the U.S. market provides us with unique insights that allow us to optimally navigate those channels to achieve market access as quickly as possible, thus providing treatments to patients who need them the most.”

To view the full research report, click here.

About Trinity Partners
Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create evidence-based solutions that drive business strategy and impact bottom lines. To learn more about Trinity Partners, click here.

Trinity’s John Greenway and Nick Simmons-Stern to Present Case Study at CBI’s Biosimilar Summit

John Greenaway, Jillian Scaife, Nick Simmons-Stern, Ali Haber, and Christina Danosi are traveling to Alexandria, Virginia this week to attend CBI’s Biosimilars Summit. At the conference, they’ll discuss how to overcome reimbursement hurdles in an expanding U.S. biosimilars market. Learn more about the event here: http://www.cbinet.com/conference/pc18014

Trinity Partners Director of Advanced Analytics, Todd Foster to Attend PMSA’s Winter Symposium

Todd Foster, Trinity’s director of advanced analytics, will attend the PMSA’s Multi-Channel Marketing Symposium in Las Vegas, January 18 – 19 2018. During the event, Todd will meet with fellow industry leaders to discuss innovative marketing practices that use data to elevate multi-channel marketing for the biotechnology, medical and pharmaceutical industries. Learn more about the event here: http://bit.ly/2FIL3MS

Trinity Partners Founder and President, John Corcoran Discusses Drug Affordability in 2018

In a recent article for Managed Healthcare Executive, reporter Mari Edlin spoke with Trinity’s John Corcoran about what he sees in the pipeline for 2018 in terms of drug affordability and pharma’s response to the matter. You can read the full article including further insights from John, here: http://bit.ly/2DHZpwg

Senior Partner Leslie Sandberg Orne Discusses Top Drugs for 2018

In a recent article for Formulary Watch, editor Christine Blank spoke with Trinity’s Leslie Sandberg Orne about new blockbuster drugs to hit the marketplace in 2018 that will treat HIV, diabetes, cancer, migraine headaches and other conditions. Check out Leslie’s insights in the full article, here: http://bit.ly/2ArPeZz

Trinity’s Herman Sanchez, Alex Chiang and Vivian DeWoskin attended the American Society of Hematology (ASH) Annual Meeting in Atlanta

On December 9th, Trinity’s Herman Sanchez, Alex Chiang and Vivian DeWoskin attended the American Society of Hematology (ASH) Annual Meeting in Atlanta, GA. During the meeting, Trinity employees had the opportunity to receive insight on evidence-based practice and decision making around malignant and non-malignant hematology, as well as the controversies associated with diagnosis and management. A full agenda of the annual meeting
can be found here: http://bit.ly/2zCT0Q5